SCHEMBL85710

SCHEMBL85710

CCOC(=O)[C@H]1CC[C@H](OC[C@@H]2CC(=O)CN2C)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TSHR P16473 2/20 0.39
GAA P10253 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 4/20 0.39
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
POLB P06746 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71866 0.81 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2PKMNPSR1TSHR
SCHEMBL71017 0.81 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2PKMNPSR1TSHR
SCHEMBL70452 0.76 PKM (0.47) ALDH1A1PKMNPSR1HSD17B10MAPT
SCHEMBL10225788 0.75 MAPT (0.40) ALDH1A1SMN1; SMN2PKMNPSR1TSHR
SCHEMBL85236 0.75 MAPT (0.40) ALDH1A1SMN1; SMN2PKMNPSR1TSHR
SCHEMBL84822 0.75 MAPT (0.40) ALDH1A1SMN1; SMN2PKMNPSR1TSHR
SCHEMBL3021911 0.73 MAPT (0.46) ALDH1A1PKMNPSR1MAPTMEN1
SCHEMBL2341343 0.72 MAPT (0.51) ALDH1A1MAPTMEN1KMT2A
SCHEMBL2345801 0.72 MAPT (0.51) ALDH1A1MAPTMEN1KMT2A
SCHEMBL2341968 0.72 MAPT (0.51) ALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 216/4885SMN1; SMN2 4739/4885KDM4E 983/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 ALDH1A1 207/4885SMN1; SMN2 4702/4885KDM4E 996/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 525/4885SMN1; SMN2 4787/4885KDM4E 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.